Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

EPX-100 Shows Promising Seizure Reduction in Ongoing Open-Label Extension Louie Pasculli

New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.

Cell Therapy Deramiocel Meets Primary End Point in Phase 3 DMD Cardiomyopathy Trial Isabella Ciccone, MPH

Capricor Therapeutics anticipates that detailed phase 3 data from the HOPE-3 study will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal.

Michael Sperling, MD, on AES Lifetime Achievement Award, Evolution in Epilepsy Care Michael R. Sperling, MD, Louie Pasculli

Michael Sperling, MD, Baldwin Keyes Professor of Neurology at Vice Chair for Research at the Sidney Kimmel Medical College, spoke about the significance of receiving the Founders Award and the current state of epilepsy.

Z-Rostudirsen Meets Primary End Point in Phase 1/2 DELIVER Trial for Duchenne Muscular Dystrophy Isabella Ciccone, MPH

Long-term treatment with z-rostudirsen over 24 months showed sustained functional improvements across all end points in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

AES Poster Showcases Feasibility of Mobile App to Track Daily Self-Reporting Epilepsy Outcomes Isabella Ciccone, MPH

A new study presented at AES 2025 reported that a cognitive-behavioral intervention via mobile application for patients with epilepsy can reliably capture daily self-reported outcomes.

FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia Isabella Ciccone, MPH

TRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.

Todays Updates

Advancing NP and PA Involvement in Pulmonary Care, CHEST Learning Susan Corbridge, PhD, Alanna Kavanugh, MSN, CCRN

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Isabella Ciccone, MPH

The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.

Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD Kassandra Holzem, MD

Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

Todays Updates

Advancing NP and PA Involvement in Pulmonary Care, CHEST Learning Susan Corbridge, PhD, Alanna Kavanugh, MSN, CCRN

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Isabella Ciccone, MPH

The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.

Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD Kassandra Holzem, MD

Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed

Latest News

New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.

Capricor Therapeutics anticipates that detailed phase 3 data from the HOPE-3 study will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal.

Michael Sperling, MD, Baldwin Keyes Professor of Neurology at Vice Chair for Research at the Sidney Kimmel Medical College, spoke about the significance of receiving the Founders Award and the current state of epilepsy.

Long-term treatment with z-rostudirsen over 24 months showed sustained functional improvements across all end points in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

A new study presented at AES 2025 reported that a cognitive-behavioral intervention via mobile application for patients with epilepsy can reliably capture daily self-reported outcomes.

TRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.

News All Time

Lacosamide Displays Positive Efficacy and Safety in Phase 2 Clinical Trial of Neonatal Seizures Louie Pasculli

Findings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.

Epidiolex CBD Treatment Effective Across Range of Developmental Epileptic Encephalopathies Marco Meglio

Recent analysis reveals Epidiolex significantly reduces seizures in patients with various developmental epileptic encephalopathies, showcasing its broad effectiveness.

Open Label Extension Confirms Cenobamate's Efficacy in Asian Populations Louie Pasculli

New data highlights cenobamate's effectiveness in reducing focal seizures in Asian populations, showcasing significant improvements and potential long-term benefits for patients.

AES Presentations Highlight Zorevunersen as Disease-Modifying Treatment for Dravet Syndrome Marco Meglio

New AES 2025 data reinforce zorevunersen’s disease-modifying potential in Dravet syndrome, showing durable seizure reduction, functional improvements, and a consistent safety profile.

NeurologyLive® Brain Games: December 7, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on autonomic dysfunction in long COVID!

Japanese Post Marketing Study Shows Long-Term Efficacy of Stiripentol in Dravet Syndrome Isabella Ciccone, MPH

Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.

NeurologyLive® Friday 5 — December 5, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.

US Survey Reveals Underuse of Dravet Syndrome–Specific Antiseizure Medications in the Clinic Isabella Ciccone, MPH

Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.

AES Poster Lays Insights Into EEG and MRI Biomarkers of MOGAD-Related Epilepsy Marco Meglio

A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease Robert Alexander, MD, Isabella Ciccone, MPH

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease Marco Meglio

A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.

Neflamapimod Reduces Plasma GFAP in Dementia With Lewy Bodies, Showing Correlation With Clinical Improvement Marco Meglio

New data highlights neflamapimod's potential in reducing biomarkers and improving clinical outcomes for dementia with Lewy bodies, paving the way for Phase 3 trials.

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease Isabella Ciccone, MPH

In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.

Recommended News For You

An Intimate Life of Medical Innovation and Charity.

Next Day Mood Is Affected by Ability to Recover From Work.

iPSC-based vaccines: A new hope for preventing and treating colorectal cancer

Women are more susceptible to the stress caused by inflation.

Short-course radiation matches standard therapy for endometrial cancer

Kate Middleton Reaches Cancer Treatment Milestone

What is a "cancer vaccine" and is it the same as a COVID vaccine?

Recommended Articles For You

Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights 

Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition 

The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond 

Unlocking the Mysteries of ICD 10 Code Normocytic Anemia 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Second opinions don't significantly delay breast cancer treatment

2.

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma

3.

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.

4.

Study identifies new approach to protect the brain during radiation therapy

5.

Oleanolic acid from grapes may increase chemotherapy effectiveness

1.

Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection

2.

Cowden Syndrome and Cancer: Understanding the Risk Factors 

3.

Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies

4.

Understanding QSOFA: A Vital Tool for Recognizing Sepsis 

5.

Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing CNS diseases at the point of diagnosis in ALK + NSCLC

2.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

3.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

4.

Navigating the Complexities of Ph Negative ALL - Part IV

5.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot